Author:
Yang Zhengjun,Zhang Bin,Hou Likun,Xie Yegong,Cao Xuchen
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. The incidences and mortalities of major cancers in china, 2009. Chin J Cancer. 2013;32:106–12.
2. Curigliano G, Goldhirsch A. The triple-negative subtype: new ideas for the poorest prognosis breast cancer. J Natl Cancer Inst Monogr. 2011;2011:108–10.
3. Brady-West DC, McGrowder DA. Triple negative breast cancer: therapeutic and prognostic implications. Asian Pac J Cancer Prev. 2011;12:2139–43.
4. Kim HR, Jung KH, Im SA, Im YH, Kang SY, Park KH, et al. Multicentre phase ii trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (kcsg br-0905). Ann Oncol. 2013;24:1485–90.
5. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA. 2006;295:2492–502.
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献